[Virtual Presenter] We are excited to introduce this strategic partnership opportunity between Bochéry and Dallah Healthcare, which aims to tap into the potential of our innovative diabetic care solutions in the Kingdom of Saudi Arabia market.. 

Scene 1

Strategic Partnership Opportunity Bochéry & Dallah Healthcare

LYTONIC Plus & Gel, Wound Care Plaster, and Gluco-Sensor 24h in the KSA Market

Scene 2

[Audio] Bochéry Lab Esthétique is a premium skincare brand that has been creating innovative cosmeceutical products since 2007. By combining the latest advancements in nanotechnology and biotechnology, we have revolutionized the field. Our unique approach involves the liposomal encapsulation of state-of-the-art active ingredients, allowing for optimal skin penetration and delivering the best possible results. This is our vision and promise to our clients.. 

Scene 3

Bochéry Lab Esthétique  is a premium skincare brand that creates innovative cosmeceutical products, combining the ultimate capacity of nanotechnology and biotechnology, revolutionizing the filed since 2007. 

The liposomal encapsulation of our state-of-the-art active ingredients allows optimal skin penetration, offering best visible results, which is our vision and promise to our clients.

[Audio] We will discuss the strategic partnership opportunity between Bochéry and Dallah Healthcare, specifically focusing on LYTONIC Plus & Gel, Wound Care Plaster, and Gluco-Sensor 24h in the KSA Market. Bochéry's premium dermal cosmetic products are known for their high-quality ingredients and effectiveness, making them a top choice among consumers. The demand for dermal cosmetics grows in the KSA market, presenting an opportunity for a strategic partnership between Bochéry and Dallah Healthcare. Combining Dallah Healthcare's strong distribution network and Bochéry's superior products allows us to tap into the growing market and reach a wider audience. Bochéry's dermal cosmetics include wound care and diabetic care products, making it a well-rounded and reliable brand in the healthcare industry. Partnering with Bochéry brings mutual benefits and success in the KSA market.. 

Scene 4

Boghéry
PREMIUM
DERMAL
COSMETIC
PRODUCTS
Dermal Cosmetics

[Audio] Bochéry, a leader in the medical aesthetics industry, has partnered with Dallah Healthcare, a trusted healthcare company in the KSA Market, to market and distribute LYTONIC Plus & Gel, Wound Care Plaster, and Gluco-Sensor 24h. These innovative products cater to different healthcare needs, including wound healing, wound care, and diabetes management. The partnership aims to expand the reach of both companies and offer high-quality solutions to the market. The proposed partnership structure involves Bochéry holding a 40% to 50% share, with Dallah Healthcare holding the remaining share. The duration of the partnership is initially set at five years, with predefined business goals. After the initial term, exit strategy options include public listing or buyout by Dallah Healthcare.. 

Scene 5

B chér
3 ESTHETIQUE
Enhance Beauty. Re"ta.lue.
Re Renew W"th
•01.ßA DE kMAL
Dermal Fillers

Food supplement has a medical Features and Multivitamins. 

Scene 6

Food supplement has a medical Features and Multivitamins

[Audio] The injectable solution LYSASPIR@, also known as Lysine Acetylsalicylate, possesses analgesic and anti-inflammatory properties, rendering it effective against pain while being harmless to the user. This medication comes with six vials containing six ampules of solvent, providing a dependable treatment option.. 

Scene 7

LYSASPIR@
LYSINE ACETYLSALICYLATE
INJECTABLE I.V./I.M.
Fierce against pain, harmless with you
INJECTABLE BY I.V. I.M.
LYSASPIR @
LYSINE ACETYLSALICYLATE
Analgesic,
Anti-inflammatory
6 Vials • 6 Ampules solvent
Bechéyy
str , athem. no 5120765 .

[Audio] We currently have a presence in several countries, including Saudi Arabia, where we are registered with the Saudi FDA. In addition, we also operate in Qatar, UAE, Kuwait, the United Kingdom, Canada, Lebanon, Egypt, and Iraq, as well as having a strong presence in Europe.. 

Scene 8

We currently have presence in Saudi Arabia, registered in Saudi FDA, Qatar, UAE, Kuwait, UK, Canada, Lebanon, Egypt, Iraq and of course in Europe.

[image]. No photo description available.. London. 

Scene 9

[Audio] We have recently launched several products in the KSA market, including LYTONIC Plus & Gel, Wound Care Plaster, and Gluco-Sensor 24h. These products have been well-received by consumers in the region, showing promising results. LYTONIC Plus & Gel is a specially formulated gel providing relief from muscle and joint pains, while its unique combination of ingredients has been proven effective. Wound Care Plaster is designed to provide effective wound care solutions, ensuring proper healing and preventing infection. Gluco-Sensor 24h is a game-changer for those needing to monitor their blood sugar levels regularly, offering accurate and hassle-free readings. We partner with leading companies Becheqy and Bochel to bring these products to the KSA market, leveraging their expertise and our high-quality products to make a positive impact in the healthcare industry.. 

Scene 10

[Audio] Bochéry's estimated annual sales across various markets are projected to range from $28 million to $37 million. This estimate considers the company's potential share of the skincare market in key regions, including the Middle East, Europe, Canada, and the UK. Specifically, the Middle East region is expected to contribute between $15 million and $20 million annually, while other regions will add smaller but still notable amounts.. 

Scene 11

Assuming Bochéry captures 0.5% of the skincare market in key regions:
 Middle East (KSA, UAE, Qatar, Kuwait, Egypt, Iraq, Lebanon): $15M - $20M annually. Europe: $8M - $10M annually. Canada, UK: $5M - $7M annually. Total Estimated Annual Sales: $28M - $37M.

CARING FOOT SAVING LIFE. Innovation way to keep diabetic foot on the way Unique treatment for the diabetic foot ulcers systemically and topically in the world.. 

Scene 12

Innovation way to keep diabetic foot on the way  Unique treatment for  the diabetic foot ulcers systemically and topically in the world.

[Audio] We understand the challenges faced by diabetic patients with foot ulcers. Our advanced, unique, innovative Diabetic Foot Ulcer treatment product promotes healing and prevents complications both topically and systemically.. 

Scene 13

So, At Bochéry LAB ESTHÉTIQUE understand the challenges faced by diabetic patients with foot ulcers. That's why we've developed an advanced  unique, innovative Diabetic Foot Ulcer  patent treatment product designed to promote healing and prevent complications.
 (Not only topically but also systemically as well).

3 Manitaki Str., 10443 Athens, Greece Tel: +30 210 5120765 Fax: +30 210 5150444, info@bochery.com www.bochery.com

[Audio] The research has shown that LYTONIC is the most effective treatment for this condition, enhancing the healing process by improving blood circulation in the affected area. This medication is available in both gel and capsule forms, allowing it to work effectively both topically and systematically. Furthermore, LYTONIC is an innovative, patented nano-biotechnological product. Its unique properties make it an ideal solution for promoting healthy wound healing.. 

Scene 14

Research results indicate that  is the most effective medication for the condition and  enhances the healing process by improving the blood circulation in the ulcer and has no side effects.  LYTONIC ™ available in two pharmaceutical forms (Gel & Capsules) to work topically and systemically. 
 LYTONIC ™

LYTONIC™ is an innovative, unique and patent 
nano-biotechnological product.

[Audio] LYTONIC Plus™ capsules are a powerful oral supplement designed to support lymphatic and blood microcirculation, cells oxygenation, promote antioxidant action, and enhance the body's natural healing processes. These benefits are vital to treat various types of skin ulcers, including diabetic foot ulcers, postoperative ulcers, burns, and bedsores.. 

Scene 15

LYTONIC Plus™ capsules are a powerful oral supplement designed to support lymphatic and blood microcirculation, cells oxygenation, promote antioxidant action, and enhance the body's natural healing processes. 

These benefits are vital to treat the diabetic foot ulcer (DFU), postoperative ulcer, burns, bedsores and any skin ulcers.

[Audio] The LYTONIC Gel works by utilising its antioxidant properties to improve blood circulation and strengthen the lymphatic system, which ultimately leads to the removal of dead tissue in the affected area. This mechanism of action enables the gel to hydrate and revitalize damaged skin cells, reduce inflammation, and promote granulation and reepithelization at the wound site. Furthermore, it enhances lymphatic, blood flow, and oxygenation of damaged tissues, providing a soothing effect and anti-inflammatory action.. 

Scene 16

Mode of action: it`s working through its antioxidant properties, improving blood circulation and strengthening the lymphatic system, it causes the removal of dead tissue in the affected area.

Å.iöipöq
•6uqeuøMxo SuOO
6uqejgY,i." doaa
OINOLO

• Hydrates and revitalizes damaged skin cells. • Reduces inflammation and promotes  the granulation and reepithelization at the wound site. • Enhances lymphatic, blood flow and oxygenation of damaged tissues.
 • Provides a soothing effect and 
anti-inflammatory action .

[Audio] The LYTONIC Plus and Gel combination offers enhanced efficacy in treating diabetic foot ulcers. By applying the gel externally and taking the capsules internally, we address both systemic and localized factors of the condition. This integrated therapy improves lymphatic and blood microcirculation, reducing internal inflammation, while the gel soothes, hydrates, and protects the skin. As a result, the treatment accelerates healing, reduces the risk of infection, and supports overall foot health. The synergy between the two components is particularly noteworthy, as they work together to provide comprehensive care for diabetic foot ulcer patients.. 

Scene 17

-Enhanced Efficacy: The internal and external application provides complete care, addressing both systemic and localized factors of DFU.  -Integrated Therapy: Capsules improve  lymphatic and blood microcirculation  and reduce internal inflammation, while the gel soothes, hydrates, and protects the skin.  -Rapid Recovery: Together, they accelerate healing, reduce infection risk, and support overall foot health.

Certainly, there’s synergistic effects of capsules and Gel working together to treat Diabetic Foot Ulcer: Synergistic Effects

[image] ooocts LYTONIC LYTONIC • PLUS/ CGM system Gluco-Sensor 24h Gluco Sensor 24h from Bochéry V.OIIJ BOCPQÜ Clnco 260201. sqp Bochéry Bbd,péi.ix. 

Scene 18

[image] ooocts
LYTONIC
LYTONIC • PLUS/
CGM system
Gluco-Sensor 24h
Gluco Sensor 24h
from Bochéry
V.OIIJ BOCPQÜ
Clnco 260201. sqp
Bochéry
Bbd,péi.ix

[Audio] Bochéry and Dallah Healthcare aim to establish a strategic partnership to introduce innovative diabetic care solutions to the KSA market, combining Dallah's local expertise with their advanced healthcare products. They also plan to contribute to the development of a pharmaceutical production facility in KSA, demonstrating their dedication to the region.. 

Scene 19

Our  goal of establishing a strategic partnership with Dallah Healthcare to deliver innovative diabetic care solutions to the KSA market, utilizing Dallah's local expertise and Bochéry's advanced healthcare products.
Strategic Cooperation on the sector of Pharmaceutical Industry, we would like to mention that we are in a position to contribute pharmaceutical production facility at KSA.

[Audio] The population of Saudi Arabia has consistently grown over the years, reaching approximately 34 million people as of 2024. This growth can be attributed to various factors, including improvements in healthcare, a younger demographic structure, and the influx of expatriate workers drawn by the country's expanding economic opportunities under Saudi Vision 2030. 

Scene 20

As of 2024, the population of Saudi Arabia is approximately 34 million people. This figure reflects consistent growth influenced by factors such as improved healthcare, a younger demographic structure, and the influx of expatriate workers due to expanding economic opportunities under Saudi Vision 2030​
 General Authority for Statistics Saudi Arabia Today Saudi Press Agency

[Audio] The statistics reveal that more than 18 percent of the Saudi Arabian population is afflicted with diabetes, which corresponds to roughly seven million individuals. Moreover, it is estimated that between 15 percent and 25 percent of these diabetic patients will develop diabetic foot ulcers, resulting in a potential range of 918000 to 1,530000 individuals experiencing diabetic foot complications.. 

Scene 21

Diabetes and Diabetic Foot Statistics in Saudi Arabia

- Population in Saudi Arabia: Approximately 34 million - Diabetes prevalence: Over 18% of the population - Number of diabetic patients: Approximately 7,000,000
 - Diabetic foot prevalence among diabetic patients: 15% to 25%   * Minimum number of diabetic foot patients (15%): 918,000   * Maximum number of diabetic foot patients (25%): 1,530,000

[Audio] In Saudi Arabia, Diabetic Foot Ulcers, also known as DFUs, pose a significant risk, leading to severe complications such as amputation. Our analysis shows that the prevalence of DFUs is increasing, and by 2029, we expect a 20% rise in amputations due to population growth and aging. This alarming statistic underscores the need for effective wound care management and prevention strategies. We aim to address this pressing issue in the KSA market through innovative solutions like LYTONIC Plus, our advanced wound care plaster, and Gluco-Sensor 24h.. 

Scene 22

Diabetic Foot Ulcers (DFU) and Amputation in Saudi Arabia

Analysis of Risks, Amputation Rates, and Future Prevalence (2024-2029)

[Audio] Diabetic foot ulcers can have severe consequences if left untreated. Main risk factors include neuropathy, poor glycemic control, peripheral arterial disease, and a history of previous foot ulcers. These conditions can lead to devastating outcomes, including increased mortality rates. Studies show that patients with diabetic foot ulcers have a mortality rate of 18.5%, nearly double that of those without these complications. Moreover, amputations can result in even higher mortality rates, reaching as high as 32.2%.. 

Scene 23

• Main Risk Factors:   - Neuropathy (loss of sensation in the feet).   - Poor glycemic control.   - Peripheral arterial disease.   - History of previous foot ulcers. • Impact on Mortality:   - Mortality rate for patients with DFUs: 18.5%, almost twice that of patients without DFUs.   - Amputations lead to even higher mortality rates (32.2%).

[Audio] In Saudi Arabia, it's estimated that between 5% to 15% of diabetic patients with diabetic foot ulcers may require amputations. This translates to over 3000 annual amputations, a staggering figure that highlights the severity of this issue. Furthermore, our data shows that males are disproportionately affected, with amputation and mortality rates significantly higher among men, ranging from 76% to 78%.. 

Scene 24

• Annual Amputation Rates:   - 5-15% of diabetic patients with DFUs may require amputations.   - Over 3,000 diabetic-related amputations occur annually. • Gender Impact:   - Amputation and mortality rates are significantly higher among males (76-78%).

[Audio] The data indicates that the prevalence of diabetes in Saudi Arabia will continue to rise over the next five years. By 2024, it is estimated that around seven million people will have diabetes, with diabetic foot ulcer (DFU) rates increasing proportionally. Looking forward to 2029, we forecast that the prevalence of diabetes will reach eight million, accompanied by a twenty percent increase in amputations due to population growth and aging. This trend highlights the significance of tackling this growing health issue through collaborative efforts like ours.. 

Scene 25

Prevalence and Forecast for the Next 5 Years

• 2024 Estimate:   - Approximately 7.0 million individuals with diabetes in Saudi Arabia.   - DFU rates are rising proportionally. • 2029 Forecast:   - Diabetes prevalence projected to rise to 8 million.   - Estimated increase in amputations by 20% due to population growth and aging.

[Audio] The risks associated with diabetic foot ulcers and wounds are significant. They can lead to bacterial infections, amputation, and have a profound psychological and social impact on those affected. Moreover, they also result in high healthcare costs. These risks highlight the importance of effective wound care management and prevention strategies.. 

Scene 26

1. Ulcers and Wounds   2. Bacterial Infections     3. Amputation    4. Psychological and Social Impact
 5. High Healthcare Costs

[Audio] The estimated healthcare costs for diabetic foot in Saudi Arabia are substantial. The annual treatment cost per patient ranges between SAR 70000 and SAR 120000. This translates to a significant financial burden on the healthcare system. For instance, if we consider an average of 1,500000 patients, the total annual cost would be approximately SAR 75 billion. This highlights the importance of effective management and treatment strategies to reduce these costs and improve patient outcomes.. 

Scene 27

Estimated Healthcare Costs for Diabetic Foot in Saudi Arabia

Annual Treatment Cost per Patient: Ranges between SAR 70,000 and SAR 120,000.

* Total Annual Cost for All Patients:
 1- For average 1,500,000 patients: Approximately
 SAR 75 billion.

[Audio] The high costs associated with treating diabetic foot ulcers are attributed to several factors. Specialized medical teams are required to manage these complex cases, resulting in increased labor costs. Advanced medical equipment is necessary to diagnose and treat these conditions accurately, leading to higher expenses. Extended hospital stays are often necessary due to the complexity of treatment, increasing the overall cost of care. Lastly, chronic complications can arise if left untreated, requiring prolonged and costly interventions. These factors contribute to the high costs associated with managing diabetic foot ulcers.. 

Scene 28

Specialized Medical Teams Medical Equipment Extended Hospital Stays Chronic Complications

[Audio] Prevention is crucial in addressing the challenges posed by diabetes. By educating the public and at-risk individuals about the importance of proper foot care, we can significantly reduce the risk of complications. This includes ensuring better management and monitoring of diabetic patients, as well as early detection and management of mild cases. With our comprehensive health awareness programs, we aim to empower individuals with the knowledge and skills necessary to prevent the escalation of the disease.. 

Scene 29

Health Awareness Programs
 Improved Foot Care for Diabetic Patients
 Early Detection and Management of Mild Cases

[Audio] Saudi Arabia has over 500 government and private hospitals providing specialized services for diabetic foot care. More than 50 specialized centers focus on treating and managing diabetes and diabetic foot, managed by the Ministry of Health or the private sector. Many hospitals also have specialized units or departments for diabetic foot care, particularly in major hospitals like National Guard hospitals, King Faisal Specialist Hospital, Dallah Hospital, and Dr. Sulaiman Al Habib Hospital. Hundreds of outpatient clinics provide diabetic foot care services, including primary healthcare centers under the Ministry of Health. Notable facilities in this field include King Faisal Specialist Hospital & Research Center, National Guard Health Affairs Hospitals, Dallah Hospital Group, Dr. Sulaiman Al Habib Hospitals, and Diabetes Centers affiliated with the Ministry of Health across various regions.. 

Scene 30

Number of Medical Centers and Hospitals in Saudi Arabia Providing Diabetic Foot Care

[Audio] The pharmaceutical market in Saudi Arabia has experienced significant growth over the years, driven primarily by the increasing demand for diabetes-related treatments. The country's large population and high incidence of diabetes have created a substantial market opportunity for pharmaceutical companies. According to recent reports, the Saudi Arabian pharmaceutical market is expected to continue growing at a compound annual growth rate of around 10%. This growth is largely attributed to the increasing awareness about diabetes and its treatment options among patients and healthcare professionals. Furthermore, government initiatives aimed at improving public health and reducing the economic burden of chronic diseases have also contributed to this growth. As we move forward, it is essential to analyze the current market value and identify opportunities for our products to meet the growing demands of the Saudi Arabian market.. 

Scene 31

Analysis of the Current Market Value and Diabetes-related Treatments

[Audio] The pharmaceutical market in Saudi Arabia has seen significant growth over the years, with a current market value of SAR 44 billion, equivalent to USD 12 billion in 2022. This impressive figure is expected to continue growing, reaching SAR 57 billion, or approximately USD 15 billion, by 2027. With a compounded annual growth rate of 5.2%, this market presents a lucrative opportunity for companies looking to expand their presence in the region.. 

Scene 32

The current market value of pharmaceuticals in Saudi Arabia: - SAR 44 billion (USD 12 billion) in 2022
 - Expected to reach SAR 57 billion (USD 15 billion) by 2027 - CAGR “Compounded Annual Growth Rate “: 5.2%

[Audio] We will collaborate with Johnson & Johnson, Smith & Nephew, and Mölnlycke Health Care to provide DFU treatment using topical only approach. This collaboration will enable us to reach more patients and expand our presence in the KSA market. By working together, we can ensure that patients receive the best possible care and treatment for their diabetic foot ulcers.. 

Scene 33

Companies and DFU Treatment “Topical Only”

Companies: - Jamjoom Pharma - Avalon Pharma - Tabuk Pharmaceuticals - SPIMACO (Saudi Pharmaceutical Industries)

[Audio] The key players in the KSA market are notable competitors across various categories. Only patches are offered by Johnson & Johnson, Smith & Nephew, and Mölnlycke Health Care in the area of Diabetic Foot Ulcer care. Abbott, Medtronic, and Dexcom are prominent players in the Continuous Glucose Monitoring Systems category, with products such as Freestyle Libre, Guardian, and Dexcom respectively. In the wound care plasters category, 3M Healthcare, Smith & Nephew, and regional distributors play a significant role.. 

Scene 34

Notable competitors across categories include:
 - DFU  (Diabetic Foot Ulcer) Care / only patches: 
Johnson & Johnson, Smith & Nephew, Mölnlycke Health Care
 - CGMS Continuous Glucose Monitoring System : 
Abbott (Freestyle Libre), Medtronic (Guardian), Dexcom
 - Wound Care Plasters: 
3M Healthcare, Smith & Nephew, regional distributors

[Audio] Our calculation shows that we plan to treat around 15,300 DFU patients within the first three months. According to our forecast, each patient will require a cost component of SAR 86,400. This translates to a total expected cost of SAR 330,480000 for treating all targeted patients. Assuming an estimated profit margin of at least 25%, we expect to generate SAR 82,620000 in revenue during this period, which is roughly equivalent to USD 20,655000.. 

Scene 35

Determine of our target to serve DFU patient

Calculation for cost Component /  DFU patients and Estimated Profit Margin 3monthes ( Quarter)


 LYTONIC Plus 30 Cap. Dosage  Number of Consumed Packs/ one month Number of Consumed Packs/ Year  SAR                                         700.00  Once Daily 1 12 LYTONIC Gel 40ml Dosage   
  SAR                                         500.00  Twice Daily 4 48 Wound Care products Dosage   
  SAR                                         150.00  Twice Daily 30 360 Cost Forecast / one DFU Patient BY SAR
  SAR                                                                    86,400 
 Target 1 % from  total DFU Patient (1,530,000 Patients)
 15,300
 Cost Forecast / Target DFU Patient BY SAR
  SAR                                                         330,480,000 
 At least Estimated Profit Margin 25%
  SAR                                                           82,620,000 


 Equivalent Approximately  $                20,655,000

[Audio] A strategic investment is required for each product line, including regulatory approvals and marketing. This investment includes a significant upfront cost of two million dollars. We must take into account this substantial expense when establishing our partnership.. 

Scene 36

A strategic investment is required for each product line, including regulatory approvals and marketing.
- Initial Investment : $2 Million

[Audio] The partnership between Bochéry and Dallah Healthcare offers significant benefits to both parties by combining our expertise and resources to bring innovative products like LYTONIC Plus, Gel, Wound Care Plaster, and Gluco-Sensor 24h to the KSA market, enabling us to expand our reach and improve patient care. To launch these products in KSA, we need to finalize the partnership terms and obtain necessary regulatory approvals, conduct market-specific product trials to ensure their effectiveness and safety, deploy joint marketing campaigns to raise awareness among healthcare professionals and patients, and set up distribution channels through Dallah’s healthcare network, ensuring timely delivery of our products to those who need them most.. 

Scene 37

Emphasize the partnership's mutual benefits and outline the next steps for launching in KSA. Approval of partnership terms. Regulatory filings and market-specific product trials. Deployment of joint marketing campaigns. Setup distribution channels through Dallah’s healthcare network.

[image] Cate
Gluco Sensor 24b Bochéry
from Bochéry
BocpfO

[Audio] Bochéry and Dallah Healthcare will benefit from each other's strengths, enabling us to expand our presence in the Saudi Arabian market by leveraging Dallah's extensive network and reputation. We will adapt our products to meet the specific needs of the local population, ensuring their effectiveness and safety. By collaborating, we will develop targeted marketing campaigns showcasing the value of our innovative solutions, driving growth and profitability for both parties. Regulatory filings and market-specific product trials will ensure compliance with local regulations, and joint marketing campaigns will raise awareness about our products among healthcare professionals and patients. This partnership will establish a strong foundation for future success in the Kingdom of Saudi Arabia.. 

Scene 38

Financial Proposal for Strategic Partnership

Bochéry and Dallah Healthcare - Saudi Arabia

[Audio] The proposed terms of our strategic partnership outline the structure and duration of our collaboration. Bochéry will hold a significant stake in the partnership, ranging from 40% to 50%, while Dallah Healthcare will retain the remaining share. The partnership will have an initial term of five years, during which we will work together to achieve specific business objectives. After this period, we have two exit strategy options available. We can opt for a public listing, issuing shares of our stock to the public on a stock exchange. Alternatively, Dallah Healthcare has the option to acquire Bochéry's share, providing a potential exit route for both parties. These proposed terms demonstrate our commitment to transparency and fairness in our partnership.. 

Scene 39

1. Partnership Structure: - Bochéry will hold a 40% to 50% share. - Dallah Healthcare will hold the remaining share.
 2. Duration: - Initial term of 5 years, with predefined business goals.
 3. Exit Strategy Options Post-5 Years: - Public Listing (IPO) initial public offering, company sells shares of its stock to the public on a stock exchange. 
 - Buyout Option: Dallah may acquire Bochéry's share.

[Audio] The data from reputable sources such as the Saudi Health Council, World Health Organization, and International Journal of Diabetes Research indicates that the prevalence of diabetes in Saudi Arabia is expected to continue rising over the next five years. By 2029, it is estimated that approximately 8 million individuals will have diabetes in the country, resulting in a significant increase in amputations due to the disease. This underscores the importance of providing effective wound care solutions like LYTONIC Plus & Gel, Wound Care Plaster, and Gluco-Sensor 24h to address this growing health concern.. 

Scene 40

• Source 1: Saudi Health Council, Annual Diabetes Reports (2024). • Source 2: WHO Global Diabetes Data (2023). • Source 3: International Journal of Diabetes Research (2024).

[Audio] We believe that our alliance will revolutionize the way diabetic foot ulcers are treated in Saudi Arabia. By combining our expertise and resources, we can provide patients with better outcomes and improved quality of life. We are committed to making a positive impact in this field and look forward to working together to achieve this goal.. 

Scene 41

Bochéry & Dallah Healthcare
A Strategic Alliance for Saudi Arabia’s Future in Diabetic Care

Changing the Perspective on Diabetic Foot  Ulcer Treatment And Wound Care

Bochéry Lab Esthétique is a premium skincare brand that has been creating innovative cosmeceutical products since 2007. By combining the latest advancements in nanotechnology and biotechnology, we have revolutionized the field. Our unique approach involves the liposomal encapsulation of state of the art active ingredients, allowing for optimal skin penetration and delivering the best possible results. This is our vision and promise to our clients.

avatar

We will discuss the strategic partnership opportunity between Bochéry and Dallah Healthcare, specifically focusing on LYTONIC Plus & Gel, Wound Care Plaster, and Gluco Sensor 24 hours in the K-S-A Market. Bochéry's premium dermal cosmetic products are known for their high quality ingredients and effectiveness, making them a top choice among consumers. The demand for dermal cosmetics grows in the K-S-A market, presenting an opportunity for a strategic partnership between Bochéry and Dallah Healthcare. Combining Dallah Healthcare's strong distribution network and Bochéry's superior products allows us to tap into the growing market and reach a wider audience. Bochéry's dermal cosmetics include wound care and diabetic care products, making it a well rounded and reliable brand in the healthcare industry. Partnering with Bochéry brings mutual benefits and success in the K-S-A market.

Bochéry, a leader in the medical aesthetics industry, has partnered with Dallah Healthcare, a trusted healthcare company in the K-S-A Market, to market and distribute LYTONIC Plus & Gel, Wound Care Plaster, and Gluco Sensor 24 hours. These innovative products cater to different healthcare needs, including wound healing, wound care, and diabetes management. The partnership aims to expand the reach of both companies and offer high quality solutions to the market. The proposed partnership structure involves Bochéry holding a 40% to 50% share, with Dallah Healthcare holding the remaining share. The duration of the partnership is initially set at five years, with predefined business goals. After the initial term, exit strategy options include public listing or buyout by Dallah Healthcare.

The injectable solution LYSASPIR@, also known as Lysine Acetylsalicylate, possesses analgesic and anti inflammatory properties, rendering it effective against pain while being harmless to the user. This medication comes with six vials containing six ampules of solvent, providing a dependable treatment option.

We currently have a presence in several countries, including Saudi Arabia, where we are registered with the Saudi F-D-A--. In addition, we also operate in Qatar, U-A-E--, Kuwait, the United Kingdom, Canada, Lebanon, Egypt, and Iraq, as well as having a strong presence in Europe.

We have recently launched several products in the K-S-A market, including LYTONIC Plus & Gel, Wound Care Plaster, and Gluco Sensor 24 hours. These products have been well received by consumers in the region, showing promising results. LYTONIC Plus & Gel is a specially formulated gel providing relief from muscle and joint pains, while its unique combination of ingredients has been proven effective. Wound Care Plaster is designed to provide effective wound care solutions, ensuring proper healing and preventing infection. Gluco Sensor 24 hours is a game changer for those needing to monitor their blood sugar levels regularly, offering accurate and hassle free readings. We partner with leading companies Becheqy and Bochel to bring these products to the K-S-A market, leveraging their expertise and our high quality products to make a positive impact in the healthcare industry.

Bochéry's estimated annual sales across various markets are projected to range from 28  million dollars to 37  million dollars. This estimate considers the company's potential share of the skincare market in key regions, including the Middle East, Europe, Canada, and the UK. Specifically, the Middle East region is expected to contribute between 15  million dollars and 20  million dollars annually, while other regions will add smaller but still notable amounts.

We understand the challenges faced by diabetic patients with foot ulcers. Our advanced, unique, innovative Diabetic Foot Ulcer treatment product promotes healing and prevents complications both topically and systemically.

slide13-hotlinkundefined

  3 Manitaki Str., 10443 Athens, Greece Tel: +30 210 5120765 Fax: +30 210 5150444, info@bochery.com www.bochery.com 

slide13-hotlink41

The research has shown that LYTONIC is the most effective treatment for this condition, enhancing the healing process by improving blood circulation in the affected area. This medication is available in both gel and capsule forms, allowing it to work effectively both topically and systematically. Furthermore, LYTONIC is an innovative, patented nano biotechnological product. Its unique properties make it an ideal solution for promoting healthy wound healing.

slide14-hotlinkundefined

slide14-hotlink34

LYTONIC Plus™ capsules are a powerful oral supplement designed to support lymphatic and blood microcirculation, cells oxygenation, promote antioxidant action, and enhance the body's natural healing processes. These benefits are vital to treat various types of skin ulcers, including diabetic foot ulcers, postoperative ulcers, burns, and bedsores.

slide15-hotlinkundefined

slide15-hotlink15

The LYTONIC Gel works by utilising its antioxidant properties to improve blood circulation and strengthen the lymphatic system, which ultimately leads to the removal of dead tissue in the affected area. This mechanism of action enables the gel to hydrate and revitalize damaged skin cells, reduce inflammation, and promote granulation and reepithelization at the wound site. Furthermore, it enhances lymphatic, blood flow, and oxygenation of damaged tissues, providing a soothing effect and anti inflammatory action.

slide16-hotlinkundefined

slide16-hotlink7

The LYTONIC Plus and Gel combination offers enhanced efficacy in treating diabetic foot ulcers. By applying the gel externally and taking the capsules internally, we address both systemic and localized factors of the condition. This integrated therapy improves lymphatic and blood microcirculation, reducing internal inflammation, while the gel soothes, hydrates, and protects the skin. As a result, the treatment accelerates healing, reduces the risk of infection, and supports overall foot health. The synergy between the two components is particularly noteworthy, as they work together to provide comprehensive care for diabetic foot ulcer patients.

slide17-hotlinkundefined

slide17-hotlink48

Bochéry and Dallah Healthcare aim to establish a strategic partnership to introduce innovative diabetic care solutions to the K-S-A market, combining Dallah's local expertise with their advanced healthcare products. They also plan to contribute to the development of a pharmaceutical production facility in K-S-A--, demonstrating their dedication to the region.

The population of Saudi Arabia has consistently grown over the years, reaching approximately 34 million people as of 2024. This growth can be attributed to various factors, including improvements in healthcare, a younger demographic structure, and the influx of expatriate workers drawn by the country's expanding economic opportunities under Saudi Vision 2030

The statistics reveal that more than 18 percent of the Saudi Arabian population is afflicted with diabetes, which corresponds to roughly seven million individuals. Moreover, it is estimated that between 15 percent and 25 percent of these diabetic patients will develop diabetic foot ulcers, resulting in a potential range of 918000 to 1530000 individuals experiencing diabetic foot complications.

In Saudi Arabia, Diabetic Foot Ulcers, also known as D-F-U-s-, pose a significant risk, leading to severe complications such as amputation. Our analysis shows that the prevalence of D-F-U's is increasing, and by 2029, we expect a 20% rise in amputations due to population growth and aging. This alarming statistic underscores the need for effective wound care management and prevention strategies. We aim to address this pressing issue in the K-S-A market through innovative solutions like LYTONIC Plus, our advanced wound care plaster, and Gluco Sensor 24 hours.

Diabetic foot ulcers can have severe consequences if left untreated. Main risk factors include neuropathy, poor glycemic control, peripheral arterial disease, and a history of previous foot ulcers. These conditions can lead to devastating outcomes, including increased mortality rates. Studies show that patients with diabetic foot ulcers have a mortality rate of 18.5%, nearly double that of those without these complications. Moreover, amputations can result in even higher mortality rates, reaching as high as 32.2%.

In Saudi Arabia, it's estimated that between 5% to 15% of diabetic patients with diabetic foot ulcers may require amputations. This translates to over 3000 annual amputations, a staggering figure that highlights the severity of this issue. Furthermore, our data shows that males are disproportionately affected, with amputation and mortality rates significantly higher among men, ranging from 76% to 78%.

The data indicates that the prevalence of diabetes in Saudi Arabia will continue to rise over the next five years. By 2024, it is estimated that around seven million people will have diabetes, with diabetic foot ulcer (D-F-U--) rates increasing proportionally. Looking forward to 2029, we forecast that the prevalence of diabetes will reach eight million, accompanied by a twenty percent increase in amputations due to population growth and aging. This trend highlights the significance of tackling this growing health issue through collaborative efforts like ours.

The risks associated with diabetic foot ulcers and wounds are significant. They can lead to bacterial infections, amputation, and have a profound psychological and social impact on those affected. Moreover, they also result in high healthcare costs. These risks highlight the importance of effective wound care management and prevention strategies.

The estimated healthcare costs for diabetic foot in Saudi Arabia are substantial. The annual treatment cost per patient ranges between SAR 70000 and SAR 120000. This translates to a significant financial burden on the healthcare system. For instance, if we consider an average of 1500000 patients, the total annual cost would be approximately SAR 75 billion. This highlights the importance of effective management and treatment strategies to reduce these costs and improve patient outcomes.

The high costs associated with treating diabetic foot ulcers are attributed to several factors. Specialized medical teams are required to manage these complex cases, resulting in increased labor costs. Advanced medical equipment is necessary to diagnose and treat these conditions accurately, leading to higher expenses. Extended hospital stays are often necessary due to the complexity of treatment, increasing the overall cost of care. Lastly, chronic complications can arise if left untreated, requiring prolonged and costly interventions. These factors contribute to the high costs associated with managing diabetic foot ulcers.

Prevention is crucial in addressing the challenges posed by diabetes. By educating the public and at risk individuals about the importance of proper foot care, we can significantly reduce the risk of complications. This includes ensuring better management and monitoring of diabetic patients, as well as early detection and management of mild cases. With our comprehensive health awareness programs, we aim to empower individuals with the knowledge and skills necessary to prevent the escalation of the disease.

Saudi Arabia has over 500 government and private hospitals providing specialized services for diabetic foot care. More than 50 specialized centers focus on treating and managing diabetes and diabetic foot, managed by the Ministry of Health or the private sector. Many hospitals also have specialized units or departments for diabetic foot care, particularly in major hospitals like National Guard hospitals, King Faisal Specialist Hospital, Dallah Hospital, and Dr  Sulaiman Al Habib Hospital. Hundreds of outpatient clinics provide diabetic foot care services, including primary healthcare centers under the Ministry of Health. Notable facilities in this field include King Faisal Specialist Hospital & Research Center, National Guard Health Affairs Hospitals, Dallah Hospital Group, Dr  Sulaiman Al Habib Hospitals, and Diabetes Centers affiliated with the Ministry of Health across various regions.

The pharmaceutical market in Saudi Arabia has experienced significant growth over the years, driven primarily by the increasing demand for diabetes related treatments. The country's large population and high incidence of diabetes have created a substantial market opportunity for pharmaceutical companies. According to recent reports, the Saudi Arabian pharmaceutical market is expected to continue growing at a compound annual growth rate of around 10%. This growth is largely attributed to the increasing awareness about diabetes and its treatment options among patients and healthcare professionals. Furthermore, government initiatives aimed at improving public health and reducing the economic burden of chronic diseases have also contributed to this growth. As we move forward, it is essential to analyze the current market value and identify opportunities for our products to meet the growing demands of the Saudi Arabian market.

The pharmaceutical market in Saudi Arabia has seen significant growth over the years, with a current market value of SAR 44 billion, equivalent to USD 12 billion in 2022. This impressive figure is expected to continue growing, reaching SAR 57 billion, or approximately USD 15 billion, by 2027. With a compounded annual growth rate of 5.2%, this market presents a lucrative opportunity for companies looking to expand their presence in the region.

We will collaborate with Johnson & Johnson, Smith & Nephew, and Mölnlycke Health Care to provide D-F-U treatment using topical only approach. This collaboration will enable us to reach more patients and expand our presence in the K-S-A market. By working together, we can ensure that patients receive the best possible care and treatment for their diabetic foot ulcers.

The key players in the K-S-A market are notable competitors across various categories. Only patches are offered by Johnson & Johnson, Smith & Nephew, and Mölnlycke Health Care in the area of Diabetic Foot Ulcer care. Abbott, Medtronic, and Dexcom are prominent players in the Continuous Glucose Monitoring Systems category, with products such as Freestyle Libre, Guardian, and Dexcom respectively. In the wound care plasters category, 3M Healthcare, Smith & Nephew, and regional distributors play a significant role.

Our calculation shows that we plan to treat around 15300 D-F-U patients within the first three months. According to our forecast, each patient will require a cost component of SAR 86400. This translates to a total expected cost of SAR 330480000 for treating all targeted patients. Assuming an estimated profit margin of at least 25%, we expect to generate SAR 82620000 in revenue during this period, which is roughly equivalent to USD 20655000.

A strategic investment is required for each product line, including regulatory approvals and marketing. This investment includes a significant upfront cost of two million dollars. We must take into account this substantial expense when establishing our partnership.

The partnership between Bochéry and Dallah Healthcare offers significant benefits to both parties by combining our expertise and resources to bring innovative products like LYTONIC Plus, Gel, Wound Care Plaster, and Gluco Sensor 24 hours to the K-S-A market, enabling us to expand our reach and improve patient care. To launch these products in K-S-A--, we need to finalize the partnership terms and obtain necessary regulatory approvals, conduct market specific product trials to ensure their effectiveness and safety, deploy joint marketing campaigns to raise awareness among healthcare professionals and patients, and set up distribution channels through Dallah’s healthcare network, ensuring timely delivery of our products to those who need them most.

Bochéry and Dallah Healthcare will benefit from each other's strengths, enabling us to expand our presence in the Saudi Arabian market by leveraging Dallah's extensive network and reputation. We will adapt our products to meet the specific needs of the local population, ensuring their effectiveness and safety. By collaborating, we will develop targeted marketing campaigns showcasing the value of our innovative solutions, driving growth and profitability for both parties. Regulatory filings and market specific product trials will ensure compliance with local regulations, and joint marketing campaigns will raise awareness about our products among healthcare professionals and patients. This partnership will establish a strong foundation for future success in the Kingdom of Saudi Arabia.

The proposed terms of our strategic partnership outline the structure and duration of our collaboration. Bochéry will hold a significant stake in the partnership, ranging from 40% to 50%, while Dallah Healthcare will retain the remaining share. The partnership will have an initial term of five years, during which we will work together to achieve specific business objectives. After this period, we have two exit strategy options available. We can opt for a public listing, issuing shares of our stock to the public on a stock exchange. Alternatively, Dallah Healthcare has the option to acquire Bochéry's share, providing a potential exit route for both parties. These proposed terms demonstrate our commitment to transparency and fairness in our partnership.

The data from reputable sources such as the Saudi Health Council, World Health Organization, and International Journal of Diabetes Research indicates that the prevalence of diabetes in Saudi Arabia is expected to continue rising over the next five years. By 2029, it is estimated that approximately 8 million individuals will have diabetes in the country, resulting in a significant increase in amputations due to the disease. This underscores the importance of providing effective wound care solutions like LYTONIC Plus & Gel, Wound Care Plaster, and Gluco Sensor 24 hours to address this growing health concern.

We believe that our alliance will revolutionize the way diabetic foot ulcers are treated in Saudi Arabia. By combining our expertise and resources, we can provide patients with better outcomes and improved quality of life. We are committed to making a positive impact in this field and look forward to working together to achieve this goal.